Floatz logo

Therapeutic Allogeneic Lymphocytes

Acute Myeloid Leukemia With t(6;9) (p23;q34.1); DEK-NUP214

Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson UniversityCell therapyPhase 2Dormant
B
56/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
41/ 100
Competitive Position
95/ 100

Competitive context

0 Active assets in the Acute Myeloid Leukemia With t(6;9) (p23;q34.1); DEK-NUP214 cohort.

Asset / SponsorPhaseRating
Busulphan
Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
Phase 2B
Fludarabine
Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
Phase 2B
TACROLIMUS
Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
Phase 2B
Cyclophosphamide
Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
Phase 2B
FILGRASTIM
Fred Hutchinson Cancer Center
Phase 2CCC

Same molecule, other indications

Therapeutic Allogeneic Lymphocytes is also rated in:

chronic myeloid leukemiaDormant
BBB
Indicative ·
72 / 100
View asset →
Relapsing Chronic Myelogenous LeukemiaDormant
BBB
Indicative ·
72 / 100
View asset →
myelodysplastic/myeloproliferative neoplasmDormant
BB
Indicative ·
70 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →